Olema Pharmaceuticals Inc. Common Stock (OLMA)
Stock · NASDAQ · Health Care
$6.58as of 10/16/2026
Price chart
Active signals
OLMA Signal Track Record
How signals performed across all stocks →What OLMA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +4.5% | 53% | September 18, 2026 |
| Bollinger Band Breakdown | 22 | -3.1% | 41% | September 15, 2026 |
| Bollinger Band Breakout | 22 | -6.9% | 32% | June 30, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -5.8% | 27% | April 24, 2026 |
| Any 20-session window (baseline) | -3.7% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal grow…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 150
- Website
- olema.com/
Fundamentals
- 1-day range
- $6.71$6.95
- Market cap
- $1.03B
- P/E (trailing)
- —
- P/E (forward)
- -2.60
- EPS (trailing)
- $-2.12
- Dividend yield
- —
- Beta
- 1.98
- Avg. volume
- 1.09M
Forecasts
10 analyst ratings
Olema Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- OLMAOlema Pharmaceuticals Inc. Common Stock$6.58▼ 4.22%Market cap $1.03BP/E —$6.61$36.26
- PCRXPacira BioSciences Inc. Common Stock$36.34▲ 0.03%Market cap $1.02BP/E 98.88$18.8$36.46
- LXRXLexicon Pharmaceuticals Inc. Common Stock$1.52▼ 7.88%Market cap $1.05BP/E —$1.1$2.68
- ANLAdlai Nortye Ltd. American Depositary Shares$11.03▼ 8.77%Market cap $1.01BP/E —$0.879$17.25
- GERNGeron Corporation Common Stock$1.17▼ 4.88%Market cap $1.01BP/E —$1.04$2.01
- AVTXAvalo Therapeutics Inc. Common Stock$11.27▼ 6.16%Market cap $989.29MP/E —$12.51$24.27
- OPKOPKO Health Inc. Common Stock$1.53▼ 4.97%Market cap $985.15MP/E —$0.98$1.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals Inc. Common Stock | $1.03B | — | $6.58 | ▼ 4.22% | $6.61$36.26 |
| PCRX Pacira BioSciences Inc. Common Stock | $1.02B | 98.88 | $36.34 | ▲ 0.03% | $18.8$36.46 |
| LXRX Lexicon Pharmaceuticals Inc. Common Stock | $1.05B | — | $1.52 | ▼ 7.88% | $1.1$2.68 |
| ANL Adlai Nortye Ltd. American Depositary Shares | $1.01B | — | $11.03 | ▼ 8.77% | $0.879$17.25 |
| GERN Geron Corporation Common Stock | $1.01B | — | $1.17 | ▼ 4.88% | $1.04$2.01 |
| AVTX Avalo Therapeutics Inc. Common Stock | $989.29M | — | $11.27 | ▼ 6.16% | $12.51$24.27 |
| OPK OPKO Health Inc. Common Stock | $985.15M | — | $1.53 | ▼ 4.97% | $0.98$1.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsightYahoo · 10/5/2026
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- Stifel Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $30Benzinga · 9/14/2026
- Get insights into the top gainers and losers of Monday's pre-market session.ChartMill · 9/14/2026
- Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial ResultsYahoo · 9/14/2026
- Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jumpYahoo · 9/14/2026
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Jason O'Byrne · September 1, 2026 · Grant650.0K
- Cyrus Harmon · July 24, 2026 · Sale12.5K @ $11.71
- Cyrus Harmon · July 23, 2026 · Sale12.5K @ $11.58
- Prakash Raman · June 18, 2026 · Grant29.5K
- Cyrus Harmon · June 18, 2026 · Grant29.5K
- Hrustanovic Gorjan · June 18, 2026 · Grant29.5K
- Larson Yi · June 18, 2026 · Grant29.5K
- Graham G. Walmsley · June 18, 2026 · Grant29.5K
- Sandra Horning · June 18, 2026 · Grant29.5K
- Garland J. Scott · June 18, 2026 · Grant29.5K
- Ian T. Clark · June 18, 2026 · Grant29.5K
- Cynthia M. Butitta · June 18, 2026 · Grant29.5K
- Andrew Rappaport · June 18, 2026 · Grant29.5K
- BIOTECHNOLOGY VALUE FUND L P · June 18, 2026 · Grant29.5K
- Prakash Raman · April 28, 2026 · Grant24.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 103.67M
- Total value held
- $1.51B
- Institutional holders
- 196
- Unknown10.39M
- Unknown8.02M
- Unknown7.47M
- Unknown7.11M
- Unknown5.65M
- Unknown5.30M
- Unknown4.76M
- Unknown4.40M
- Unknown3.94M
- Unknown3.21M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
OLMA Joins 12 Healthcare Stocks Moving in Pre-Market
OLMA was among 12 healthcare stocks that moved in Wednesday's pre‑market session, signaling early interest from traders. The move comes while the stock sits near its 52‑week low and a low RSI of 19.1, suggesting it may be oversold. This early activity could reflect new market sentiment or a reaction to broader healthcare sector dynamics.
OLMA Joins 12 Healthcare Stocks Moving in Pre-Market. OLMA was among 12 healthcare stocks that moved in Wednesday's pre‑market session, signaling early interest from traders. The move comes while the stock sits near its 52‑week low and a low RSI of 19.1, suggesting it may be oversold. This early activity could reflect new market sentiment or a reaction to broader healthcare sector dynamics.